Aveanna Healthcare Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVAH research report →
Range $9.5 – $16
Price Chart
About the company
Aveanna Healthcare Holdings Inc. operates as a diverse platform for home-based care services throughout the United States. The company delivers a range of critical offerings, including private duty nursing (PDN), adult home health and hospice care, in-home pediatric therapy, and enteral nutrition services.
- CEO
- Jeffrey S. Shaner
- IPO
- 2021
- Employees
- 35,500
- HQ
- Atlanta, GA, US
Get TickerSpark's AI analysis on AVAH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.89B
- P/E
- 10.00
- Fwd P/E
- 18.77
- PEG
- 0.01
- P/S
- 1.11
- P/B
- 10.06
- EV/EBITDA
- 14.37
- Div Yield
- 0.00%
- Gross Margin
- 31.95%
- Op Margin
- 11.12%
- Net Margin
- 10.56%
- ROE
- 150.20%
- ROIC
- 15.32%
Latest fiscal year · YoY change
- Revenue
- $2.43B+20.2%
- Gross Profit
- $805.15M+26.7%
- Op Income
- $265.38M
- Net Income
- $225.03M+2159.1%
- EPS
- $1.10+2040.0%
- OCF Growth
- +274.5%
- FCF Growth
- +336.2%
- 52W High
- $13.36
- 52W Low
- $5.93
- 50D MA
- $9.28
- 200D MA
- $8.14
- Beta
- 1.93
- RSI (14)
- 81
- Avg Volume
- 2.37M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aveanna delivered double-digit revenue growth, raised full-year guidance, and pointed to improving reimbursement, labor, and payer mix momentum across its core businesses.· August 13, 2026
- Q2 revenue was $670.5 million, up 13.7% year over year; adjusted EBITDA was $95.4 million, up 8%.
- Consolidated gross margin was 32.6%, with management saying margin should stay broadly consistent even as revenue grows.
- Private duty services got 7 state rate enhancements so far, California now has a 2027 Medicaid rate increase, and PDS preferred payer MCO volume reached 64%.
- Home health episodic mix stayed high at about 81%, with total episodic volume up 18.5% and home health/hospice revenue up 14.8%.
- Management raised 2026 guidance to revenue greater than $2.68 billion and adjusted EBITDA greater than $365 million, and lifted long-term organic growth targets in PDS and home health/hospice.
Revenue for Q2 was $670.5 million, up 13.7% year over year. Adjusted EBITDA was $95.4 million, up 8% year over year. Consolidated gross margin was $218.5 million, or 32.6%. By segment, home health and hospice revenue rose 14.8%, private duty services revenue rose 14.0%, and medical solutions revenue rose 9.4%. Management said Q2 benefited from improved rate and volume environments, operational efficiencies, and better caregiver hiring/retention trends. For 2026, Aveanna raised guidance to revenue greater than $2.68 billion and adjusted EBITDA greater than $365 million. Management also raised long-term organic growth targets to 5% to 6% for private duty services, 8% to 10% for home health and hospice, and kept medical solutions at 8% to 10%.
Jeffrey Shaner framed the quarter as evidence that Aveanna’s preferred payer and government reimbursement strategy is working. He emphasized that demand in home and community-based care remains strong and that the company is shifting caregiver capacity toward payers willing to support enhanced reimbursement and value-based arrangements. He also highlighted California’s 2027 pediatric private duty nursing rate increase as the final piece in a multi-year state advocacy effort, calling it a meaningful milestone for both access and staffing.
Matthew Buckhalter said Q2 revenue reached $670.5 million and adjusted EBITDA was $95.4 million, while consolidated gross margin was 32.6%. He pointed to PDS gross margin of 28.9%, home health and hospice gross margin of 53.9%, and medical solutions gross margin of 45.1%, saying margins were in line with expectations and should remain in a similar range. On the balance sheet, Aveanna ended Q2 with about $433 million of liquidity, including $97 million of cash, and generated $85.3 million of operating cash flow and $75.4 million of free cash flow year to date; the company also repriced its term loan by 75 basis points, which should cut annual interest expense by about $10 million.
Analysts focused on whether the higher long-term growth targets imply higher margins, and management said gross margin percentages should stay roughly consistent because wage pass-through remains central to the model. They also pressed on California, and management said the final 2027 rate schedule should be updated by the end of September, with wage increases expected to begin in late Q3 or Q4 before the new rate takes effect on January 1, 2027. On M&A and leverage, management said Family First was already funded with cash on hand, that the pipeline remains robust, and that the long-term goal is still to get below 3x leverage.
The bull case from this call is that Aveanna appears to be turning reimbursement wins into real volume growth across all three segments. Management sounded increasingly confident about labor supply, payer mix, and state/federal rate visibility, and it believes California could unlock additional staffing and patient flow. The company also has strong cash generation, upgraded credit ratings, and room for disciplined M&A.
The main risks are still labor constraints, dependence on reimbursement improvements, and the possibility that wage pass-through limits margin expansion. Management acknowledged that California’s final rate details are still pending and that the wage increase will be phased in before the new reimbursement starts, which could pressure near-term economics. There is also execution risk in integrating Family First and in continuing to balance growth, margins, and leverage while pursuing acquisitions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 21.6%
- Shares Outstanding
- 217.76M
- Float Shares
- 47.09M
of shares held by institutions
198 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bain Capital Investors LLC | 81.60M | 0 |
| J.H. Whitney Equity Partners Vii, LLC | 27.06M | ▼ 9.18M |
| Nut Tree Capital Management, LP | 12.92M | 0 |
| Blackrock, Inc. | 7.41M | ▲ 1.91M |
| Vanguard Group Inc | 5.58M | ▲ 1.54M |
| Ophir Asset Management Pty Ltd | 5.10M | ▲ 5.10M |
| Vanguard Capital Management LLC | 3.67M | ▼ 301.60K |
| Braidwell LP | 3.07M | ▲ 861.60K |
| Boston Partners | 2.87M | ▲ 46.91K |
| Citadel Advisors LLC | 2.29M | ▲ 2.01M |
| Dimensional Fund Advisors LP | 2.26M | ▲ 923.31K |
| Mackenzie Financial Corp | 2.11M | ▲ 1.58M |
Held by 195 ETFs
Biggest fund positions in AVAH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | WILLIAMS ROBERT M JR | sell | 2,419,035 |
| Jun 30, 26 | WILLIAMS ROBERT M JR | sell | 525,844 |
| Jun 30, 26 | WILLIAMS ROBERT M JR | sell | 55,121 |
| Jun 30, 26 | VIGANO PAUL R | sell | 2,419,035 |
| Jun 30, 26 | VIGANO PAUL R | sell | 525,844 |
| Jun 30, 26 | VIGANO PAUL R | sell | 55,121 |
| Jun 30, 26 | J.H. Whitney Equity Partners VII, LLC | sell | 2,419,035 |
| Jun 24, 26 | WILLIAMS ROBERT M JR | sell | 919,389 |
| Jun 24, 26 | WILLIAMS ROBERT M JR | sell | 72,963 |
| Jun 24, 26 | WILLIAMS ROBERT M JR | sell | 7,648 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVAH coverage
Recent articles, reports, and earnings notes.
No research on AVAH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVAH report →AVAH Q2 Earnings Call Highlights Higher Growth Targets
zacks.com · Aug 14
Aveanna Healthcare Holdings Inc. (AVAH) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 13
Aveanna Healthcare: Q2 Earnings Report Boosts The Stock And Reinforces My Buy Rating
seekingalpha.com · Aug 13
Aveanna Healthcare Q2 Earnings Call Highlights
marketbeat.com · Aug 13
Aveanna (AVAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Aug 13
Aveanna Healthcare (AVAH) Beats Q2 Earnings and Revenue Estimates
zacks.com · Aug 13
Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2026 Guidance
globenewswire.com · Aug 13
Will Lower PDS Margin Affect Aveanna Healthcare's Q2 Earnings?
zacks.com · Aug 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.